biostudies-literatureFreiberg MSNCATS NIH HHSNHLBI NIH HHSRRD VANIAAA NIH HHS536-546https://www.ebi.ac.uk/biostudies/studies/S-EPMC5541383biostudies-literatureUnknown2(5)<h4>Importance</h4>With improved survival, heart failure (HF) has become a major complication for individuals with human immunodeficiency virus (HIV) infection. It is unclear if this risk extends to different types of HF in the antiretroviral therapy (ART) era. Determining whether HIV infection is associated with HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), or both is critical because HF types differ with respect to underlying mechanism, treatment, and prognosis.<h4>Objectives</h4>To investigate whether HIV infection increases the risk of future HFrEF and HFpEF and to assess if this risk varies by sociodemographic and HIV-specific factors.<h4>Design, setting, and participants</h4>This study evaluated 98 015 participants without baseline cardiovascJAMA cardiologyAssociation Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study.PMC5541383U01 AA020790K01 HL134147R01 HL125032UL1 TR001863I01 RX000667U24 AA020794R01 HL095136Bachmann JMBedimo RJGoetz MBChang CHLeaf DRodriguez-Barradas MBrown STTindle HAAlcorn CSo-Armah KATracy RPBrandt CAVasan RSDuVall SLRimland DJustice ACGibert CLPatterson OVFreiberg MSSkanderson MOursler KAButt AACrothers KWarner AGottlieb SGottdiener JfalseAssociation Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study.<h4>Importance</h4>With improved survival, heart failure (HF) has become a major complication for individuals with human immunodeficiency virus (HIV) infection. It is unclear if this risk extends to different types of HF in the antiretroviral therapy (ART) era. Determining whether HIV infection is associated with HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), or both is critical because HF types differ with respect to underlying mechanism, treatment, and prognosis.<h4>Objectives</h4>To investigate whether HIV infection increases the risk of future HFrEF and HFpEF and to assess if this risk varies by sociodemographic and HIV-specific factors.<h4>Design, setting, and participants</h4>This study evaluated 98 015 participants without baseline cardiovasc2017-01-01T00:00:00Z2017 May2025-04-04T02:58:02.727Z2019-03-27T02:52:31ZS-EPMC55413832838466010.1001/jamacardio.2017.0264